Iferanserin

Cat. No.:HY-118557CAS No.:58754-46-4Molecular Formula: $C_{23}H_{28}N_2O$ Molecular Weight:348.48Target:5-HT ReceptorPathway:GPCR/G Protein; Neuronal SignalingStorage:4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 mo and light)	e and light onth (sealed storage, away from moisture
---	---

SOLVENT & SOLUBILITY

		Mass Solvent Concentration	1 mg	5 mg	10 mg		
	Preparing Stock Solutions	1 mM	2.8696 mL	14.3480 mL	28.6961 mL		
		5 mM	0.5739 mL	2.8696 mL	5.7392 mL		
		10 mM	0.2870 mL	1.4348 mL	2.8696 mL		
	Please refer to the so	Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2.5 mg/mL (7.17 mM); Suspended solution; Need ultrasonic						
		one by one: 10% DMSO >> 90% cor g/mL (7.17 mM); Clear solution	n oil				

BIOLOGICAL ACTIVITY		
Description	Iferanserin (S-MPEC) is a selective 5-HT receptor (serotonin receptor) antagonist with an affinity for 5-HT _{2A} receptor. Iferanserin has the potential for internal hemorrhoid disease treatment ^[1] .	
IC ₅₀ & Target	5-HT _{2A} Receptor	
In Vitro	An intra-anal ointment application of Iferanserin might modify the vascular effects occurring in hemorrhoid disease and thereby reduce or eliminate the most frequently occurring symptoms of hemorrhoid disease ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

Product Data Sheet



REFERENCES

[1]. Herold A, et al. Intra-anal Iferanserin 10 mg BID for hemorrhoid disease: a prospective, randomized, double-blind, placebo-controlled trial. Clin Ther. 2012 Feb;34(2):329-40.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA